Abstract
Background: Some studies have described a large number of hypertensive patients who are followed by a primary care physician without achieving adequate blood pressure (BP) control but whose treatment nevertheless is not intensified. It is not known whether physicians are aware of this clinical inertia and what factors are associated with this problem.
Objective: The aim of this study was to describe the factors associated with clinical inertia in hypertensive patients.
Methods: This was an observational, cross-sectional, multicentre study conducted in a network of primary care centres and hospital hypertension units in Spain. Using a consecutive sampling approach, 512 physicians selected 5077 hypertensive patients in whom they suspected poor BP control after chart review. The main variables documented were BP control and cardiovascular risk according to European Society of Hypertension guidelines, changes in treatment after visit, type of treatment, and healthcare setting. A binomial logistic regression multivariate analysis, adjusted for physician, was performed.
Results: Of the selected patients, 70.9% had poor BP control according to measurements taken in the physician’s office, and in 1499 (42.1%) of those poorly controlled patients, treatment was not intensified (clinical inertia). Factors associated with clinical inertia were as follows: being seen at a primary care centre (p<0.001), not having left ventricular hypertrophy (p<0.001) or microalbuminuria (p<0.001), taking fixed-dose (p=0.049) or free-dose (p=0.001) combination therapy, BP measured in other settings (nurse’s office, patient’s home) than the physician’s office (p=0.034) or the pharmacy (p=0.019), older age (p=0.032), and lower systolic (p<0.001) and diastolic (p<0.001) BP. Of the hypertensive patients with clinical inertia, 90.2% (95% CI 88.7, 91.7) had high cardiovascular risk.
Conclusions: Clinical inertia was associated with a profile that included older age, lack of co-morbid conditions and being seen at a primary care centre.
Similar content being viewed by others
References
Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001 Nov 6; 135(9): 825–34
Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP; National Heart, Lung, and Blood Institute; National High BP Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP. Hypertension 2003 Dec; 42(6): 1206–52
Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States [published erratum appears in Arch Intern Med 2007 Apr 9; 167 (7): 648]. Arch Intern Med 2007 Jan 22; 167(2): 141–7
Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hypertens (Greenwich) 2000 Oct; 2(5): 324–30
Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of BP in a hypertensive population. N Engl J Med 1998 Dec 31; 339(27): 1957–63
Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006 Sep; 48(3): 385–91
Nasser SA, Lai Z, O’Connor S, et al. Does earlier attainment of BP goal translate into fewer cardiovascular events? Curr Hypertens Rep 2008 Oct; 10(5): 398–404
Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 BP control goals. Hypertension 2006 Mar; 47(3): 345–51
Phillips LS, Twombly JG. It’s time to overcome clinical inertia. Ann Intern Med 2008 May 20; 148(10): 783–5
Roumie CL, Elasy TA, Greevy R, et al. Improving BP control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med 2006 Aug 1; 145(3): 165–75
Redón J, Coca A, Lázaro P, et al. Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J Hypertens 2010 Aug; 28(8): 1770–7
Redon J, Brunner HR, Ferri C, et al. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens Suppl 2008 Dec; 26(4): S1–14
Steinman MA, Fischer MA, Shlipak MG, et al. Clinician awareness of adherence to hypertension guidelines. Am J Med 2004 Nov 15; 117(10): 747–54
Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002 Feb 25; 162(4): 413–20
Ferrari P, Hess L, Pechere-Bertschi A, et al. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens 2004 Jun; 22(6): 1221–9
Márquez-Contreras E, Coca A, de la Figuera von Wichmann M, et al., Control-Project Researchers. Cardiovascular risk profile of uncontrolled hypertensive patients: the Control-Project study. Med Clin (Barc) 2007 Jan 27; 128(3): 86–91
Ferrari P. National Coordinators for the Reasons for not Intensifying Antihypertensive Treatment (RIAT) trial 12. Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens 2009 Mar; 23(3): 151–9
Bramlage P, Thoenes M, Kirch W, et al. Clinical practice and recent recommendations in hypertension management: reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin 2007 Apr; 23(4): 783–91
Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Intern Med 2007 Dec; 22(12): 1648–55
Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [published erratum appears in J Hypertens dy2007 Aug; 25 (8): 1749]. J Hypertens 2007 Jun; 25(6): 1105–87
O’Brien E, Asmar R, Beilin L, et al., European Society of Hypertension Working Group on BP Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home BP measurement. J Hypertens 2003 May; 21(5): 821–48
Maiques Galán A, Villar Alvarez F, Brotons Cuixart C, et al.; Grupo de Prevención Cardiovascular del PAPPS. Preventive cardiovascular recommendations. Aten Primaria 2007 Nov; 39Suppl. 3: 15–26
Gil-Guillén V, Orozco-Beltrán D, Pérez RP, et al. Clinical inertia in diagnosis and treatment of hypertension in primary care: quantification and associated factors. Blood Press 2010 Feb; 19(1): 3–10
Lüders S, Schrader J, Schmieder RE, et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Eur J Cardiovasc Prev Rehabil 2010 Jun; 17(3): 271–9
Cushman WC, Ford CE, Cutler JA, et al., ALLHAT Collaborative Research Group. Success and predictors of BP control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002 Nov–Dec; 4(6): 393–404
Mancia G, Laurent S, Agabiti-Rosei E, et al., European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27(11): 2121–58
Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal BP on the risk of cardiovascular disease. N Engl J Med 2001 Nov 1; 345(18): 1291–7
Lewington S, Clarke R, Qizilbash N, et al., Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published erratum appears in Lancet 2003 Mar 22; 361 (9362): 1060]. Lancet 2002 Dec 14; 360(9349): 1903–13
Arguedas JA, Perez MI, Wright JM. Treatment BP targets for hypertension. Cochrane Database Syst Rev 2009 Jul 8; (3): CD004349
Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998 May 21; 338(21): 1516–20
Parchman ML, Pugh JA, Romero RL, et al. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med 2007 May–Jun; 5(3): 196–201
Llisterri Caro JL, Rodríguez Roca GC, Alonso Moreno FJ, et al.; Grupo de Trabajo de Hipertension Arterial de la Sociedad Española de Medicina Rural y Generalista (Grupo HTA/SEMERGEN); Investigadores del Estudio PRESCAP 2002. BP control in Spanish hypertensive patients in Primary Health Care Centres. PRESCAP 2002 Study [in Spanish]. Med Clin (Barc) 2004 Feb 14; 122(5): 165–71
Rodríguez Roca GC, Artigao Ródenas LM, Llisterri Caro JL, et al. Control of hypertension in elderly patients receiving primary care in Spain. Rev Esp Cardiol 2005 Apr; 58(4): 359–66
Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines?. A framework for improvement. JAMA 1999 Oct 20; 282(15): 1458–65
Jamerson K, Weber MA, Bakris GL, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359(23): 2417–28
Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of BP in patients with hypertension. Cochrane Database Syst Rev 2010 Mar 17; (3): CD005182
Gorostidi M, Sobrino J, Segura J, et al., Spanish Society of Hypertension ABPM Registry Investigators. Ambulatory BP monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens 2007 May; 25(5): 977–84
Kerr EA, Zikmund-Fisher BJ, Klamerus ML, et al. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med 2008 May 20; 148(10): 717–27
Howes F, Hansen E, Williams D, et al. Barriers to diagnosing and managing hypertension-a qualitative study in Australian general practice. Aust Fam Physician 2010 Jun–Jul; 39(6): 511–6
Acknowledgements
The authors wish to thank all the physicians who have been involved in the INERCAP (Inercia Clínica) study and the SEH-LELHA (Sociedad Española de Hipertensión — Liga Española para la Lucha contra la Hipertensión Arterial) Compliance Group. The authors would also like to express their gratitude to Almirall S.A., Barcelona, Spain, for its unrestricted grant, which contributed to the funding of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gil-Guillén, V., Orozco-Beltrán, D., Márquez-Contreras, E. et al. Is There a Predictive Profile for Clinical Inertia in Hypertensive Patients?. Drugs Aging 28, 981–992 (2011). https://doi.org/10.2165/11596640-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11596640-000000000-00000